Compare Johnson & Johnson (JNJ) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs MINISO Group Holding Ltd — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while MINISO Group Holding Ltd trades at $11.93 (market cap $3.62B). The key difference: Johnson & Johnson is far larger — about 173× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| JNJ | MNSO | |
|---|---|---|
Market Cap | $626.09B | $3.62B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $26.63 |
52-Week Low | $172.78 | $11.30 |
Enterprise Value | $654.37B | $4.29B |
Dividend Yield | 2.06% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
MNSO trades at $11.895, down 4.99% in the last session amid a neutral technical outlook. Recent earnings show volatility with a Q1 2026 beat but Q3 and Q4 2025 misses, while fundamentals reveal solid revenue growth to $21.44 billion in 2025 and a net income margin of 8.98%. The company announced a $2 billion share repurchase program in June 2026, signaling confidence.
The stock presents a mixed outlook: valuation ratios like P/E of 12.16 appear reasonable, and analyst consensus is 75% buy, but risks include margin pressure from SG&A growth and competitive retail dynamics. Near-term price action hinges on Q2 2026 earnings delivery against expectations of $0.2754 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
